Abstract 181P
Background
Leiomyosarcoma (LMS) is a highly aggressive and rare malignancy, often presenting as large tumors with potentially heterogeneous tumor microenvironment (TME). This TME heterogeneity may contribute to poor responsiveness to immunotherapy and its overall unfavorable prognosis. We aimed to provide a detailed characterization of the intratumoral heterogeneity and possible mechanisms of non-responsiveness to immune checkpoint inhibitors in large LMS.
Methods
We investigated four large treatment-naïve LMS (ten samples/tumor). We analyzed four regions: vital and necrotic centers (VC, NC), organ-adjacent and free margins (O-AM, FM), where we evaluated T cells, macrophages, immune inhibitory molecules, and tertiary lymphoid structures (TLS) by IHC and flow cytometry. Moreover, we performed unsupervised clustering of flow cytometry data and analyzed cytokine secretion after anti-LAG-3 blockade in each tumor sample. Lastly, factorial analysis of mixed data (FAMD) analysis revealed the drivers of tumor sample variability.
Results
The expression of PD-1 and PD-L1 profoundly varied within the same tumor tissue. TLS were detected only at the tumor margins. Interestingly, TLS were present in one out of ten samples in one LMS tissue. Moreover, shared immune patterns were detected in specific tumor regions, such as higher levels of IDO, absence of specific macrophage subpopulation, and lower levels of PD-1 and LAG-3 expression in the O-AM. Following the findings about LAG-3 expression, we tested the cell's reactivity to anti-LAG-3 blockade. This blockade enhanced IL-8 in the NC and PD-L1 in the O-AM compared to other tumor regions. FAMD showed that samples can be separated by the tumor regions, where VC and NC displayed distinct patterns.
Conclusions
Our findings emphasize the importance of multiple biopsies to accurately assess the immune heterogeneity in large LMS. The intratumoral heterogeneity may explain varied responses to immunotherapy, even with low or absent expression of these molecules. A single biopsy may not capture the full spectrum of immune cell infiltration, potentially leading to incomplete evaluations. Advanced immunoprofiling offers deeper insights into the TME, improving diagnostic accuracy and treatment selection. AZV NU23J-08–00031, GA UK 94323.
Legal entity responsible for the study
University Hospital Motol, Prague, Czech Republic.
Funding
Czech Health Research Council NU23J-08-0031, Charles University in Prague - 94323.
Disclosure
J. Bartunkova: Financial Interests, Personal, Full or part-time Employment and a minority shareholder: Sotio Biotech, a.s. All other authors have declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract